setmelanotide · Imcivree

Peptide

Also known as RM-493, BIM-22493

Approvedregulatory verdict

Evidence outlook

Approved: Obesity (label: acquired hypothalamic obesity, Bardet-Biedl syndrome, and POMC, PCSK1 or LEPR deficiency obesity), Bardet-Biedl Syndrome, Hypothalamic Obesity

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Prader-Willi Syndrome · Phase 2 · investigational in the US

Also approved (5)
JP
  • Acquired hypothalamic obesity (first therapy approved in Japan for it)
Product first approved 2026finviz.com
CA
  • Weight management in patients 6 years and older with obesity due to Bardet-Biedl syndrome or genetically confirmed POMC, PCSK1 or LEPR deficiency
Product first approved 2023finance.yahoo.com
EU
  • Obesity and control of hunger with genetically confirmed POMC/PCSK1 or LEPR deficiency, and Bardet-Biedl syndrome; later extended to acquired hypothalamic obesity
  • Obesity and control of hunger with genetically confirmed Bardet-Biedl syndrome, adults and children from 2 years
  • Obesity and control of hunger in acquired hypothalamic obesity, from 4 years (extension)
Product first approved 2021EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (9)
Bardet-Biedl Syndrome
NCT05194124 · Rhythm Pharmaceuticals, Inc.
2021-12-21 – 2023-10-19 · Bardet-Biedl Syndrome, POMC Deficiency
What this study did
Hypothalamic Obesity
NCT06760546 · Rhythm Pharmaceuticals, Inc.
2025-09-23 – 2028-03-13 · Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome
What this study did
Obesity
NCT05093634 · Rhythm Pharmaceuticals, Inc.
2022-04-26 – 2026-06-30 · Obesity, Genetic Obesity
What this study did
NCT06596135 · Rhythm Pharmaceuticals, Inc.
2024-10-21 – 2026-06-24 · Obesity Associated With Defects in Leptin-melanocortin Pathway
What this study did
Phase 2/3 (1)
Obesity
NCT03651765 · Rhythm Pharmaceuticals, Inc.
2018-07-15 – 2025-01-09 · Obesity Associated With Defects in Leptin-melanocortin Pathway
What this study did
Phase 2 (9)
Hypothalamic Obesity
NCT04725240 · Rhythm Pharmaceuticals, Inc.
2021-06-07 – 2022-06-28 · Hypothalamic Obesity
What this study did
Obesity
NCT07496463 · Massachusetts General Hospital
2026-07-21 – 2027-04-30 · Pseudohypoparathyroidism Type 1a, Obesity
What this study did
NCT04963231 · Rhythm Pharmaceuticals, Inc.
2021-11-30 – 2024-09-30 · Genetic Obesity
What this study did
NCT03013543 · Rhythm Pharmaceuticals, Inc.
2017-02-10 – 2022-03-01 · Genetic Obesity, Obesity, Obesity Due to Melanocortin 4 Receptor Deficiency
What this study did
NCT03262610 · Rhythm Pharmaceuticals, Inc.
2017-08-15 – 2018-01-31 · Hypertriglyceridemia, Obesity
What this study did
NCT01749137 · Rhythm Pharmaceuticals, Inc.
2013-01-14 – 2013-09-28 · Overweight
What this study did
Prader-Willi Syndrome
NCT06772597 · Rhythm Pharmaceuticals, Inc.
2025-03-04 – 2030-10-30 · Prader-Willi Syndrome, Obesity, Hyperphagia
What this study did
NCT02311673 · Rhythm Pharmaceuticals, Inc.
2015-03-19 – 2016-10-26 · Prader-Willi Syndrome
What this study did
Other / comorbidity
NCT02507492 · Charite University, Berlin, Germany
2015-01 – 2018-07 · Homozygous or Compound Heterozygous POMC, LEPR or PCSK1 Gene Mutation
What this study did
Phase 1/2 (1)
Obesity
NCT02041195 · Rhythm Pharmaceuticals, Inc.
2014-01 – 2014-12 · Overweight and Obesity
What this study did
Phase 1 (3)
Obesity
NCT01867437 · Rhythm Pharmaceuticals, Inc.
2013-05 – 2014-03 · Obesity, Morbid Obesity
What this study did
NCT02431442 · Rhythm Pharmaceuticals, Inc.
2012-01 – 2014-01 · Overweight, Obese
What this study did
Other / comorbidity
NCT04348175 · Rhythm Pharmaceuticals, Inc.
2020-07-09 – 2021-04-17 · Renal Insufficiency
What this study did
Phase 4 (2)
Bardet-Biedl Syndrome
NCT07674290 · Tom Hühne
2023-01-01 – 2030-12-31 · Bardet Biedl Syndrome (BBS), Bardet Biedl Syndrome, Bardet-Biedl Syndrome (BBS), Alstrom Syndrome
What this study did
Other / comorbidity
NCT05046132 · Rhythm Pharmaceuticals, Inc.
2021-08-05 – 2022-04-07 · Healthy
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Hypothalamic Obesity: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Setmelanotide (Imcivree): this drugApprovedPeptideMC4RReliable signal
NCT05774756: Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984)
BivamelagonPhase 2Small moleculeMC4RPartial signal
NCT06046443: Mean % change in BMI at Week 14: 600mg -9.3% (p=0.0004), 400mg -7.7% (p=0.0002), 200mg -2.7% (p=0.0180), placebo +2.2%

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Imcivree (setmelanotide) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
Phase 3ObesityRecruiting
Est. primary completion 2027-03-13 · NCT06760546 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2ObesityEnrolling by invitation
Est. primary completion 2027-04-30 · NCT07496463 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 4ObesityRecruiting
Est. primary completion 2030-12-31 · NCT07674290 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 September 2026ApprovalHealth Canada approves IMCIVREE for acquired hypothalamic obesity
CA, Health Canada · Rhythm Pharmaceuticals, Inc. · Source ↗
24 August 2026ApprovalJapan MHLW approves IMCIVREE for acquired hypothalamic obesity
JP, MHLW · Source ↗
11 August 2026ApprovalMHRA expands Imcivree authorisation to acquired hypothalamic obesity
UK, MHRA · Source ↗
16 March 2026Topline resultPhase 3 EMANATE: none of the four substudies met its primary endpoint